Immunogen
Executive Summary
Receives option for exclusive license from Takeda for chemotherapeutic maytansine, a highly toxic compound which Immunogen will use in a monoclonal antibody conjugate. Cambridge, Mass.-based Immugen plans to be in the clinic within six weeks.